Increased titres of anti-nuclear antibodies do not predict the development of associated disease in the absence of initial suggestive signs and symptoms

Scandinavian Journal of Rheumatology

Volumn 36, Issue 6, 2007, Pages 448-451

  Dinser, R ^a,b   Braun, A ^b   Jendro, M C ^a   Engel, A ^b,c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CELL NUCLEUS ANTIGEN; EXTRACTABLE NUCLEAR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; ENCEPHALOMYELITIS; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCREENING; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 37349061328     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701406577     Document Type: Article

References (15)

1. Emren W, O'Neill L. Clinical significance of antinuclear antibodies. Arthritis Rheum 1997;40:1612-18.
2. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Int Med 1996;156:1421-5.
3. Wiik AS. Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005;34:122-4.
4. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
5. Myckatyn SO, Russell AS. Outcome of positive antinuclear antibodies in individuals without connective tissue disease. J Rheumatol 2003;30:736-9.
6. Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997;49:857-61.
7. Macgeorge J, Frazer IH, Cunninham A. Autoantibodies, sheep cell agglutinins and anti-albumin antibodies in alcoholic liver disease. J Clin Lab Immunol 1984;13:21-4.
8. Blaes F, Klotz M, Huwer H, Straub U, Kalweit G, Schimrigk K, et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000;69:254-8.
9. Guyomard S, Salles G, Coudurier M, Rousset H, Coiffier B, Bienvenu J, et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. Br J Haematol 2003;123:90-9.
10. Pinsky MR. Dysregulation of the immune response in severe sepsis. Am J Med Sci 2004;328:220-9.
11. Tektonidou MG, Anapliotou M, Vlachoyiannopoulos P, Moutsopoulos HM. Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. Ann Rheum Dis 2004;63:1159-61.
12. Vaile JH, Dyke L, Kherani R, Johnston C, Higgins T, Russell AS. Is high titre ANA specific for connective tissue disease? Clin Exp Rheumatol 2000;18:433-8.
13. Suarez-Almazor ME, Gonzalez-Lopez L, Gamez-Nava JI, Belseck E, Kendall CJ, Davis P. Utilisation and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. J Rheumatol 1998;25:1980-5.
14. Maddison PJ, Stephens C, Briggs D, Welsh KI, Harvey G, Whyte J, et al. Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. Medicine 1993;72:103-12.
15. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in 'healthy' individuals. Arthritis Rheum 1997;40:1601-11.